Asceneuron SA’s Post

#Asceneuron_sa announces $100 million oversubscribed Series C financing! We have successfully secured a Series C financing, led by Novo Holdings with new investment from EQT Group Life Sciences, OrbiMed and SR One Capital Management Capital Management, alongside participation from existing investors M Ventures , Sofinnova Partners, GSK Equities Investment Limited and Johnson & Johnson Innovation JJDC Inc. The funds will be used to advance our lead asset #ASN51, an oral small molecule drug designed to inhibit #OGA into Phase 2 clinical development for the treatment of Alzheimer’s disease. Click here https://lnkd.in/d278vevG to read the press release and discover more about Asceneuron’s groundbreaking clinical pipeline of O-GlcNAcase inhibitors for the treatment of #neurodegenerative diseases. #neurodegeneration #ALS #alzheimers #parkinson #dementia #financing

𝐄𝐧𝐠𝐫𝐚𝐢𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐑𝐚𝐢𝐬𝐞𝐬 $𝟏𝟓𝟕𝐌 𝐢𝐧 𝐎𝐯𝐞𝐫𝐬𝐮𝐛𝐬𝐜𝐫𝐢𝐛𝐞𝐝 𝐒𝐞𝐫𝐢𝐞𝐬 𝐁 𝐑𝐨𝐮𝐧𝐝 Engrail Therapeutics Engrail Therapeutics, a precision neuroscience company, closed a $157 million Series B financing round co-led by F-Prime Capital F-Prime Capital, Forbion Forbion, and Norwest Venture Partners Norwest Venture Partners, with participation from other investors. Since 2019, the company has raised over $220 million. The funding will advance the pipeline targeting diseases like anxiety disorders, depression, PTSD, and rare neurodegenerative diseases. CEO Vikram Sudarsan Vikram Sudarsan expressed gratitude for strong investor support, especially from Pivotal Life Sciences, and highlighted plans for ongoing studies and pipeline development. New board members from F-Prime, Forbion, Norwest, RiverVest RiverVest Venture Partners, and Red Tree Ventures Red Tree Venture Capital bring valuable expertise to Engrail. Stacie Weninger of F-Prime sees significant potential in Engrail's pipeline, while Peter Bisgaard, chairman of Engrail's board, reflects on the company's rapid progression. #Neuroscience #PrecisionMedicine #Biotech #SeriesB #Investment #Healthcare #Therapeutics #ClinicalTrials #Anxiety #Depression #PTSD #NeurodegenerativeDiseases

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> Alto Neuroscience, Fractyl Health go public in Friday IPO doubleheader: Two more biotechs will go public Friday morning as Alto Neuroscience and Fractyl Health build on the momentum created by CG Oncology and ArriVent BioPharma’s Nasdaq listings last week. California drugmaker Alto Neuroscience raised about $128.6 million in its upsized NYSE listing, as the mid-stage CNS biotech priced at $16 apiece $ANRO, the high end of the range it proposed earlier this week. Fractyl Health, meanwhile, landed on the Nasdaq with $110 million in proceeds by pricing at $15 a share $GUTS, the mid-point of the range it disclosed on Monday. The listings come as investors and private life sciences startups look for greener pastures in 2024 after two years of icy conditions in the public markets and belt-tightening for venture-backed drug development. Alto and Fractyl will follow standout debuts from Phase III cancer biotechs CG and ArriVent, which traded handsomely above the initial asking price in their first days of trading last Thursday and Friday, respectively. Amit Etkin For Alto, an IPO is expected to carry it into the pivotal stage of drug development. The company is in multiple mid-stage studies for its major depressive disorder candidates, and it has a PDE4 inhibitor licensed from Sanofi for cognitive impairment associated with schizophrenia. The Los Altos, CA-based startup will have enough money to last at least another 24 months with the IPO proceeds; it had about $51 million in cash and equivalents at the end of last September. Its biggest owners are Alpha Wave Ventures, Apeiron Investment Group, Amit Etkin and Dan Segal. Etkin, Alto’s president and CEO, co-founded the biotech with Segal in 2019. Alto’s listing adds to a drumbeat of financings for psychiatry drugmakers, including Neumora’s IPO last fall and nine-figure rounds for MapLight Therapeutics and Rapport Therapeutics. Big Pharma is also dishing out billions to get its hands-on schizophrenia drugmakers Karuna Therapeutics and Cerevel Therapeutics. Lexington, MA-based Fractyl has spent more than a decade in diabetes and obesity, an area of the cardiometabolic field that has gained a surge of R&D interest thanks to the success of Novo Nordisk’s semaglutide franchise and Eli Lilly’s tirzepatide-based medicines. Fractyl has an endoscopic procedural therapy in late-stage testing in the US for inadequately controlled type 2 diabetes. The product, known as Revita, is in a pilot commercial launch in Germany. Behind that, it has an AAV pancreatic gene therapy that will enter the clinic in the first half of next year for type 2 diabetes. It will then follow up with a gene therapy for obesity. The IPO will pad its runway through 2025. The obesity field almost had an IPO last December in Carmot Therapeutics,… #lucidquest #genetherapy #celltherapy

🚨 Breakthrough in Neurodegenerative Disease Research! 🚨 LoQus23 Therapeutics Ltd, a Cambridge-based biotech, just raised £35M in Series A funding to advance its groundbreaking work in small molecule drugs. 🧬 The round was led by Forbion, with participation from SV Health Investors’ SV Dementia Discovery Fund (DDF) and Novartis Venture Fund (NVF). Forbion’s Rogier Rooswinkel will also join LoQus23's Board of Directors. 🎯 What’s next? Pre-clinical development and initial clinical studies of their lead program: an allosteric small molecule MutSβ inhibitor 🔬 LoQus23, led by Dr David Reynolds, Dr Caroline Benn, and Dr Ruth McKernan, is pioneering small molecule somatic expansion inhibitors aimed at treating Huntington’s Disease and other triplet repeat disorders. Their cutting-edge approach targets DNA instability to slow down neurodegeneration. With 30,000 patients in the U.S. alone suffering from Huntington’s disease, this innovative approach could offer hope where no disease-modifying treatment currently exists. 💡 📢 Stay tuned to Future Techly for the latest updates on this groundbreaking initiative and the latest in tech and business! 💥 Source: FinSMEs #Biotech #Neuroscience #HuntingtonsDisease #DrugDiscovery #LoQus23 #Forbion #HealthTech #CambridgeInnovation #NeurodegenerativeResearch #Pharma #FutureTechly

Mark you calendar and register! In this CURE Epilepsy and ILAE-YES webinar we will be discussing about common data elements and their use in preclinical research. Honored to be part of this panel! Register here: https://lnkd.in/euhrenE6

🚀 Exciting News in Alzheimer’s Research! 🧠 Switzerland-based biotech company Asceneuron SA has just secured a whopping $100 million in a series C funding round. The investment was led by Novo Holdings, along with participation from EQT Life Sciences Dementia Fund, OrbiMed, and SR One. 🌐 What’s the Buzz? Asceneuron’s lead asset, an oral small molecule drug called ASN51, targets intracellular tau—a protein associated with Alzheimer’s disease. The drug has already shown promise in phase 1 trials, demonstrating uptake by the central nervous system and impact on the OGA enzyme. Now, with this influx of cash, Asceneuron aims to advance ASN51 into a phase 2 trial. 📊 Why Is This Important? ASN51’s unique mode of action and convenient oral formulation could give it an edge over existing Alzheimer’s treatments. While Biogen and Eisai offer intravenous options, Asceneuron’s approach offers hope for a paradigm shift in Alzheimer’s therapy. 🌟 What’s Next? Stay tuned as Asceneuron embarks on the midstage study for ASN51 in the second half of this year. As CEO Barbara Angehrn Pavik puts it, this potential breakthrough could significantly expand treatment options for patients with Alzheimer’s disease. 🙌 To read more about this development click here: https://lnkd.in/e8zBMpV6 #CRO #Contractresearch #Alzheimers #clinicaltrials

🎉 Halia Therapeutics Shines at BIO Investor Forum 2024! 🧠 We're pleased to share that our CEO, Dr. David J. Bearss, participated yesterday in the panel Expansion of Neurodegenerative Disease Targets and Pipelines at the BIO Investor Forum 2024. It was a great opportunity to discuss the future of targeting neurodegenerative diseases with other industry leaders. Dr. Bearss highlighted our innovative work with HT-4253, targeting LRRK2 to address neuroinflammation in Alzheimer's and Parkinson's diseases. We're excited about the positive reception and look forward to advancing our mission of developing novel treatments for patients in need. #HaliaTx #Neurodegeneration #BioInvestorForum #AlzheimersResearch #ParkinsonsResearch #Biotech

Mesa Mayor Giles said it best: "This investment brings dozens of well-paying jobs to our city, boosting our local economy and enhancing our reputation as a hub for innovation." This new Mesa facility, along with another in Pennsylvania, will bring cutting-edge research, development, and manufacturing capabilities under one roof, giving Nucleus and its partners a huge time and scale advantage. For our city, this means: - Economic Growth: The facility is expected to create about 50 high-paying jobs, contributing to local economic development and reinforcing Mesa’s growing reputation as a hub for innovation. - Improved Patient Access: Radiopharmaceuticals often have short half-lives, meaning they need to be produced near where they’re used. Having this facility in Mesa ensures faster and more reliable access to life-saving therapies for patients across the Southwest. - National Impact: By addressing supply chain constraints and accelerating drug development timelines, Nucleus’ expansion will not only benefit Mesa but also improve patient outcomes across the country. Faster clinical trials and reduced time-to-market for new therapies could be game-changing for healthcare. Awesome to see City of Mesa contributing to such groundbreaking work that will impact the future of healthcare nationwide. City of Mesa Office of Economic Development #MesaAZ #Arizona #EconomicDevelopment #EconDev #Innovation

#ICYMI Endeavor BioMedicines had an exciting Q2 as we continue to advance our #lungdisease and #oncology pipelines. Thanks to our employees, investors and supporters, we had the opportunity to welcome important new hires, raised $132.5 million in oversubscribed Series C financing, and presented Phase 2a clinical trial data for our idiopathic pulmonary fibrosis (#IPF) drug candidate at the American Thoracic Society 2024 International Conference. Learn more here: https://bit.ly/4cm0B7X      #Biotechnews #investors #science #clinicaltrials